• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Why Nextracker Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket

    2/1/24 7:51:14 AM ET
    $AEY
    $BFRG
    $CNXA
    $DB
    Office Equipment/Supplies/Services
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEY alert in real time by email

    Shares of Nextracker Inc. (NASDAQ:NXT) rose sharply during today’s pre-market trading after the company reported better-than-expected third-quarter financial results.

    Nextracker reported quarterly earnings of 96 cents per share which beat the analyst consensus estimate of 48 cents by 100%. Revenue clocked in at $710.43 million, topping the Street's estimate of $617.95 million, a 38.38% increase over sales of $513.37 million from the same period last year, according to data from Benzinga Pro.

    Nextracker shares surged 19.7% to $54.20 in pre-market trading

    Here are some other stocks moving in pre-market trading.

    Gainers

    • Elevai Labs, Inc. (NASDAQ:ELAB) gained 85.3% to $1.26 in pre-market trading after gaining 8% on Wednesday.
    • Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) shares jumped 52.1% to $0.8420 in pre-market trading. Kiora Pharmaceuticals announced a private placement of up to $45 million.
    • Oragenics, Inc. (NYSE:OGEN) gained 17.6% to $2.71 in pre-market trading after dipping around 34% on Wednesday. Oragenics recently announced termination of at-market offering program.
    • TROOPS, Inc. (NASDAQ:TROO) shares gained 14.8% to $2.16 in pre-market trading after falling over 6% on Wednesday.
    • Dunxin Financial Holdings Limited (NYSE:DXF) shares rose 12.2% to $0.3960 in pre-market trading.
    • TransCode Therapeutics, Inc. (NASDAQ:RNAZ) shares rose 10% to $0.76 in pre-market trading. TransCode Therapeutics regained compliance with the Nasdaq.
    • Nuvve Holding Corp. (NASDAQ:NVVE) shares climbed 9.7% to $1.36 in pre-market trading. Nuvve shares fell over 62% on Wednesday after the company announced pricing of its $9.6 million underwritten public offering.
    • FibroBiologics, Inc. (NASDAQ:FBLG) shares gained 9.7% to $31.95 in pre-market trading. FibroBiologics announced direct listing on the NASDAQ.
    • Deutsche Bank Aktiengesellschaft (NYSE:DB) shares gained 5.8% to $13.60 in pre-market trading after the company posted fourth-quarter results and announced plans to cut 3,500 jobs. Deutsche Bank plans to increase both share repurchases and dividends by at least 50% year-over-year in 2024.

    Losers

    • Revelation Biosciences, Inc. (NASDAQ:REVB) shares dipped 48.7% to $4.50 in pre-market trading after gaining more than 10% on Wednesday.
    • Infobird Co., Ltd (NASDAQ:IFBD) shares fell 31.6% to $0.93 in pre-market trading after surging over 115% on Wednesday.
    • Bullfrog AI Holdings, Inc. (NASDAQ:BFRG) fell 25.4% to $3.64 in pre-market trading after declining 9% on Wednesday. Bullfrog AI Holdings recently filed shelf offering of 786,938 shares and accompanying warrants at $6.63 per share and accompanying warrant.
    • Volcon, Inc. (NASDAQ:VLCN) shares fell 20.5% to $0.1069 in pre-market trading after the company announced a 1-for-45 reverse stock split.
    • Connexa Sports Technologies Inc. (NASDAQ:CNXA) declined 17.3% to $0.3310 in pre-market trading. Connexa Sports Technologies shares jumped 101% on Wednesday after the company announced it regained compliance with the Nasdaq minimum shareholder equity rule.
    • Earlyworks Co., Ltd (NASDAQ:ELWS) fell 14.9% to $0.4748 after surging more than 55% on Wednesday.
    • MaxLinear, Inc. (NYSE:MXL) shares dipped 13.4% to $18.00 in pre-market trading after reporting fourth-quarter results.
    • ADDvantage Technologies Group, Inc. (NASDAQ:AEY) shares declined 13.4% to $1.60 in pre-market trading.
    • Trinity Biotech plc (NASDAQ:TRIB) shares fell 12.4% to $0.5170 in pre-market trading after surging 34% on Wednesday. Trinity Biotech reported third-quarter results and announced acquisition of the CGM assets of Waveform Technologies, Inc.
    • ING Groep N.V. (NYSE:ING) shares declined 8.7% to $12.97 in pre-market trading following fourth-quarter results.

     

    Now Read This: Top 5 Energy Stocks That May Crash This Quarter

    Get the next $AEY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AEY
    $BFRG
    $CNXA
    $DB

    CompanyDatePrice TargetRatingAnalyst
    ING Group N.V.
    $ING
    2/2/2026Hold → Buy
    Deutsche Bank
    Nextpower Inc.
    $NXT
    1/28/2026$142.00Sector Weight → Overweight
    KeyBanc Capital Markets
    Nextpower Inc.
    $NXT
    1/28/2026$88.00 → $105.00Hold
    TD Cowen
    ING Group N.V.
    $ING
    1/27/2026Hold
    Jefferies
    Nextpower Inc.
    $NXT
    10/24/2025$65.00 → $88.00Hold
    TD Cowen
    Nextpower Inc.
    $NXT
    10/22/2025$102.00Buy
    Needham
    Nextpower Inc.
    $NXT
    10/22/2025Buy → Neutral
    Guggenheim
    Nextpower Inc.
    $NXT
    10/21/2025$114.00Neutral → Buy
    Citigroup
    More analyst ratings

    $AEY
    $BFRG
    $CNXA
    $DB
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Corporate Controller & PAO Kwong Connie H. was granted 10,933 shares, increasing direct ownership by 19% to 69,085 units (SEC Form 4)

    4 - MAXLINEAR, INC (0001288469) (Issuer)

    2/23/26 6:53:46 PM ET
    $MXL
    Semiconductors
    Technology

    Chairman, President and CEO Seendripu Kishore was granted 105,867 shares, increasing direct ownership by 14% to 876,651 units (SEC Form 4)

    4 - MAXLINEAR, INC (0001288469) (Issuer)

    2/23/26 6:53:30 PM ET
    $MXL
    Semiconductors
    Technology

    Officer Litchfield Steven G was granted 45,419 shares, converted options into 29,315 shares and covered exercise/tax liability with 42,532 shares, increasing direct ownership by 24% to 388,038 units (SEC Form 4)

    4 - MAXLINEAR, INC (0001288469) (Issuer)

    2/23/26 6:53:38 PM ET
    $MXL
    Semiconductors
    Technology

    $AEY
    $BFRG
    $CNXA
    $DB
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President and COO Smith Ted C. bought $20,606 worth of shares (7,155 units at $2.88), increasing direct ownership by 126% to 12,855 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/23/24 5:09:54 PM ET
    $NVVE
    Electrical Products
    Industrials

    President and COO Smith Ted C. bought $10,802 worth of shares (3,928 units at $2.75), increasing direct ownership by 222% to 5,700 units (SEC Form 4)

    4 - Nuvve Holding Corp. (0001836875) (Issuer)

    12/20/24 5:24:40 PM ET
    $NVVE
    Electrical Products
    Industrials

    Director Stengone Carmine N. bought $4,600 worth of shares (1,250 units at $3.68) (SEC Form 4)

    4 - KIORA PHARMACEUTICALS INC (0001372514) (Issuer)

    9/12/24 6:32:55 AM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $BFRG
    $CNXA
    $DB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ING Groep upgraded by Deutsche Bank

    Deutsche Bank upgraded ING Groep from Hold to Buy

    2/2/26 12:18:03 PM ET
    $ING
    Commercial Banks
    Finance

    Nextpower upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Nextpower from Sector Weight to Overweight and set a new price target of $142.00

    1/28/26 7:11:59 AM ET
    $NXT
    Industrial Machinery/Components
    Industrials

    TD Cowen reiterated coverage on Nextpower with a new price target

    TD Cowen reiterated coverage of Nextpower with a rating of Hold and set a new price target of $105.00 from $88.00 previously

    1/28/26 6:49:46 AM ET
    $NXT
    Industrial Machinery/Components
    Industrials

    $AEY
    $BFRG
    $CNXA
    $DB
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OCI Energy and Arava Power have closed construction financing with ING Capital to support a 347 MWdc solar energy project near Houston

    SAN ANTONIO, Feb. 23, 2026 (GLOBE NEWSWIRE) -- OCI Energy LLC ("OCI Energy"), Arava Power, and ING Capital LLC ("ING") (together, the "Companies") today announced the successful close of construction financing for Project SunRoper, a 347 MWdc solar project located in Wharton County, Texas. This is the second such transaction between OCI Energy and ING, previously having worked together on financing for the Alamo City Battery Energy Storage System project, and the first among the three Companies. Project SunRoper is being developed through a joint venture between OCI Energy and Arava Power, a pioneer in Israel's solar energy sector. The Companies selected ING Capital to underwrite the fina

    2/23/26 4:42:54 PM ET
    $ING
    Commercial Banks
    Finance

    TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

    BOSTON, Feb. 23, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers, today announced the publication of a manuscript titled Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy in the journal Molecular Imaging and Biology. The paper, published February 19, 2026, reports on a novel tumor-selective immunotherapy approach that activates innate immune signaling specifically within cancer cells while enabling non-invasive imaging of drug delivery. The study was carried out in collaboration with Dr. Anna Moore, Professor, Dire

    2/23/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

    DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares ("MVPHS") of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nas

    2/20/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEY
    $BFRG
    $CNXA
    $DB
    SEC Filings

    View All

    SEC Form 6-K filed by ING Group N.V.

    6-K - ING GROEP NV (0001039765) (Filer)

    2/24/26 6:05:04 AM ET
    $ING
    Commercial Banks
    Finance

    TransCode Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    2/23/26 8:10:39 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bullfrog AI Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - BullFrog AI Holdings, Inc. (0001829247) (Filer)

    2/20/26 8:28:41 PM ET
    $BFRG
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $BFRG
    $CNXA
    $DB
    Leadership Updates

    Live Leadership Updates

    View All

    Treasury Guidance Supports T1's Tax Credit Eligibility

    AUSTIN, Texas and NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- T1 Energy Inc. (NYSE:TE) ("T1," "T1 Energy," or the "Company") supports policy that favors the revival of advanced American manufacturing and energy dominance in accordance with the One Big Beautiful Bill Act ("OBBBA"). The initial guidance provided by the U.S. Department of Treasury last week on the implementation of the OBBBA foreign entity of concern ("FEOC") provisions is consistent with T1's expectations and supports T1's analysis of its eligibility for Section 45X tax credits. "T1 is an American-owned and controlled company committed to investing in advanced American manufacturing, building a domestic and non-FEOC solar s

    2/17/26 6:10:23 AM ET
    $GLW
    $NXT
    $TE
    Telecommunications Equipment
    Industrials
    Industrial Machinery/Components
    Miscellaneous

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AEY
    $BFRG
    $CNXA
    $DB
    Financials

    Live finance-specific insights

    View All

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Minimum Market Value of Publicly Held Shares

    DUBLIN, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 19, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company no longer meets the requirement in Nasdaq Listing Rule 5450(b) that listed securities maintain a minimum market value of publicly held shares ("MVPHS") of $15,000,000, based on Nasdaq's review of the Company's MVPHS for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on the Nas

    2/20/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Receives Non-Compliance Notice Regarding Nasdaq Global Select Requirement for Nasdaq Minimum Bid Price Requirement

    DUBLIN, Feb. 13, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, received notice on February 11, 2026 from the Nasdaq Stock Market LLC ("Nasdaq") that the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), requiring that listed securities maintain a minimum bid price of $1.00 per share, based on the closing bid price of the Company's American Depositary Shares ("ADSs") for the last 30 consecutive business days. This notice has no immediate effect on the listing of the Company's ADSs, which will continue to trade at this time on

    2/13/26 5:00:00 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    Trinity Biotech Secures Regulatory Approval for Commencement of Upstream Manufacturing Activities of Uni-Gold™ HIV Rapid Test Under Its Offshored and Outsourced Model, Supporting Financial Performance Transformation

    Approval Marks Final Regulatory Milestone Required to Enable Launch of Upstream Manufacturing Activities Under New Offshored & Outsourced Production Model Expected to Drive Gross Margin Expansion, Improve Working Capital Efficiency, and Enhance Long‑Term Scalability  Represents a Key Final Component of the Company's Comprehensive Transformation Plan DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (NASDAQ:TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, today announced it has now received full regulatory approval for the commencement of upstream manufacturing activities for

    2/10/26 1:28:10 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care

    $AEY
    $BFRG
    $CNXA
    $DB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Kiora Pharmaceuticals Inc.

    SC 13G/A - KIORA PHARMACEUTICALS INC (0001372514) (Subject)

    11/14/24 7:17:24 PM ET
    $KPRX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Trinity Biotech plc

    SC 13D/A - TRINITY BIOTECH PLC (0000888721) (Subject)

    11/14/24 5:26:28 PM ET
    $TRIB
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care